A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Cisplatin or Carboplatin will be given on day 1 every 21 days for 6 cycles; Gemcitabine will
be given on day 1 and day 8 every 21 days for 6 cycles. Those patients that do not progress
on GC after 6 cycles of chemotherapy will be started on erlotinib daily until disease
progression. A cycle of erlotinib will be 28 days. Patients who progress on GC will be
offered erlotinib as well,in order to evaluate its activity as a single-agent in the
second-line setting.
Patients previously treated with GC have reported a progression-free survival (PFS) of 9
months. We would anticipate an extension of PFS to 12 months in patients treated with GC
followed by maintenance erlotinib. Furthermore, we hypothesize that patients who achieved
benefit from GC therapy would have further response when treated with maintenance erlotinib,
such that this strategy may increase the likelihood of attaining long-term survival.